 |
|
|
| |
Raltegravir (RAL) Pharmacokinetics (PK) and Safety in HIV-1 Exposed Neonates at High Risk of Infection (IMPAACT P1110)
|
| |
| |
Reported by Jules Levin
17th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy
June 8-10, 2016, Washington, DC, USA
D.F. Clarke1, E.P. Acosta2, A. Chain3, J. Wang4, S.A. Spector5, Y.J. Bryson6, H. Teppler7, S. Popson8, B. Graham8, M.E. Smith9, R. Hazra10, M. Mirochnick11
1Boston Medical Center, Pediatric Infectious Diseases, Boston, USA; 2Univ of Alabama at Birmingham, Pharmacology and Toxicology, Birmingham, USA; 3Merck Research Laboratories, Pharmacology, North Wales, USA; 4Harvard School of Public Health, Biostatistics, Boston, USA; 5Univ of California at San Diego, Pediatrics, San Diego, USA; 6Univ of California at Los Angeles, Pediatrics, Los Angeles, USA; 7Merck Research Laboratories, Clinical Research, North Wales, USA; 8FSTRF, Research, Amherst, USA; 9NIH, NIAID, Bethesda, USA; 10NIH, NICHD, Bethesda, USA; 11Boston University, Pediatrics, Boston, USA
|
| |
|
|
|
|
|
